Brachytherapy with radiation and immunotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combining brachytherapy (a type of internal radiation) with immunotherapy (nivolumab) for people with advanced esophageal cancer that has not fully responded to initial chemoradiation. The goal is to see if this targeted approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old and your daily activities are not severely limited (ECOG 0-2).
- You have a type of esophageal cancer called squamous cell carcinoma that has spread to nearby tissues or lymph nodes (stage III or IVA).
- You have already had external beam radiation and chemotherapy with platinum and fluoropyrimidine, but the cancer did not fully go away or came back, and surgery is not an option.
- You have not had immunotherapy before, and you have already started your first dose of nivolumab after chemoradiation.
- Your tumor tests positive for PD-L1 (a protein that helps cancer hide from the immune system) in at least 1% of tumor cells.
- You have at least one tumor that can be measured or seen on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of targeted radiation (SBRT) and immunotherapy for people with esophageal cancer that has spread to a few spots in the body. The goal is to see if this approach helps control the cancer and improves your well-being.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
This trial compares the usual treatment (chemotherapy plus radiation before surgery) with a combination that also includes an immunotherapy drug called sintilimab. The goal is to see if adding immunotherapy helps shrink the tumor and improve outcomes for patients with esophageal cancer that can be removed by surgery.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.